Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA 510(k)

The NOxBOXi Nitric Oxide Delivery System

K-Number: K201339 · 2020-06-19

ApplicantPraxair, Inc.
Decision Date2020-06-19
Product CodeMRN
Advisory CommitteeAN
DecisionSubstantially Equivalent

Device Summary

The NOxBOXi Nitric Oxide Delivery System is a medical device manufactured by Praxair, Inc.. It received FDA 510(k) clearance on 2020-06-19 under approval number K201339. The device is classified under product code MRN. It was reviewed by the AN advisory panel. FDA Decision: Substantially Equivalent.

Frequently Asked Questions

What is the The NOxBOXi Nitric Oxide Delivery System?

The NOxBOXi Nitric Oxide Delivery System is a medical device that received FDA 510(k) clearance on 2020-06-19. It is manufactured by Praxair, Inc.. The 510(k) number is K201339.

When was The NOxBOXi Nitric Oxide Delivery System approved by the FDA?

The NOxBOXi Nitric Oxide Delivery System received FDA 510(k) clearance on 2020-06-19, under approval number K201339.

What company makes The NOxBOXi Nitric Oxide Delivery System?

The NOxBOXi Nitric Oxide Delivery System is manufactured by Praxair, Inc..

What is the FDA product code for The NOxBOXi Nitric Oxide Delivery System?

The FDA product code for The NOxBOXi Nitric Oxide Delivery System is MRN.

Related Clinical Trials

NCT07039942 French Prospective Multicentric Study in Real World RECRUITING NCT06728059 Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm COMPLETED NCT07458243 A Prospective, Multicenter, Single Arm Registry of ENROUTE NPS in Conjunction With Carotid WALLSTENT in Chinese Population NOT_YET_RECRUITING NCT07430293 Hybrid Closed-Loop Insulin Delivery After Pancreatectomy RECRUITING NCT04414280 The Impact of Hybrid Closed-loop Insulin Delivery in Type 1 Diabetes on Glycemic Control and PROMs ACTIVE_NOT_RECRUITING NCT06847542 A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD RECRUITING

Related Devices (Code: MRN)

K171696NOxBOXi Nitric Oxide Delivery SystemPraxair Distribution, Inc. K200389INOmax DSIR PlusMallinckrodt Manufacturing, LLC K193481AeroNOx 2.0 Nitric Oxide Titration & Monitoring SystemInternational Biomedical K220898NOxBOXi Nitric Oxide Delivery SystemLinde Gas & Equipment, Inc. K222930Evolve Nitric Oxide Delivery SystemMallinckrodt Manufacturing, LLC K231823NOxBOXi Nitric Oxide Delivery SystemLinde Gas & Equipment, Inc.

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.

↑